Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications

Fig 4

Comparative adverse event-profile of two tyrosine kinase inhibitors.

The largest relative differences in the RRRs of either nilotinib or imatinib are visualized for selected adverse events. The blue arrow indicates adverse events which are stronger associated with imatinib than nilotinib, the ruby arrow vice versa. Both groups are separated by the dotted line.

Fig 4